A pharmacist by training, I have spent three decades in industry and over 15 years at AstraZeneca focusing on improving the lives of people with cardiovascular, renal and metabolic (CVRM) diseases.

At AstraZeneca I have had the chance to work across the full spectrum of drug development, helping me hone both my clinical and commercial acumen. Roles have included Product Lead in Early and Late-stage CVRM drug development, Global Commercial Director and Pricing and Market Access Director. I have supported drug approvals, investment decisions, IPOs, clinical deals and health authority negotiations.

I thrive on developing high-performing teams with entrepreneurial and innovative mindsets. Together, we have made significant scientific breakthroughs, including pioneering the development of antisense oligonucleotide and beta-cell imaging for regenerative therapies in diabetes. With the growing burden of cardiovascular, metabolic and renal diseases around the world, I am proud to lead projects teams with a focus on finding novel targets to stop progression of these devastating diseases.

Working with both clinical and commercial colleagues, I thrive on developing high-performing teams with entrepreneurial and innovative mindsets.

Tina Rydén-Bergsten Global Product Leader, Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
Headshot of Tina Rydén-Bergsten, Global Product Leader, AstraZeneca

CURRENT ROLE

Global Product Leader, Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca

2011 - 2021

Global Product Leader in Early CVRM and Director of Drug Development Late CVRM, AstraZeneca.

2008 – 2010

Global Marketing Director, Emerging CV & GI

2007-2008

Global Brand Strategy Director, Emerging CV & GI

  Featured publications

Does lowering the blood pressure improve the mood?

Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Wiklund I, Halling K, Rydén-Bergsten T, Fletcher A. Blood Pressure 1997;6:357-64.

Hjärtsvikt kostar!

Andersson F, Rydén-Bergsten T. Läkartidningen 1997;94:2828-30

ACE inhibitors and heart failure; the consequences of underprescribing.

Andersson F, Cline C, Rydén-Bergsten T, Erhardt L. Pharmacoeconomics. 1999 Jun;15(6):535-50.

The health care costs of heart failure in Sweden.

Andersson F, Rydén-Bergsten T. Journal of Internal Medicine 1999;246:275-284

Quelle influence l’abaissement de la pression artériell a-t-il sur la qualité de vie?

Wiklund I, Halling K, Rydén-Bergsten T. Arch Mal Coeur 1999;92:1079-82

Angiotensin converting enzyme (ACE) inhibitors and heart failure.

Andersson F, Cline C, Rydén-Bergsten T, Erhardt L. Parmacoeconomics 1999; 15:535-550

Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study.

Venskutonyte L, Brismar K, Rydén-Bergsten T, Rydén L, Kjellström B. Diab Vasc Dis Res. 2013 May;10(3):263-9. 

Effect of tenapanor on interdialytic weight gain in patients on hemodialysis.

Block, G, Rosenbaum, D, Leonsson-Zachrisson, M, Stefansson, B, Rydén-Bergsten, T, Greasley, P, Johansson, S, Knutsson, M, Carlsson, B. CJASN. 2016;11(6)

Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.

King, A, Siegel, M, Rydén-Bergsten, T, et al. Science Translational Medicine 2018: 10(456)

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

Stanko Skrtic, Björn Tyrberg, Malin Broberg, Hans Ericsson, Volker Schecke, Magnus Kjaer, Marcus Hompesch, Eva-Marie Andersson, Erik Ryberg, Alexander Aivazidis, Charlotte Wennberg Huldt, Lars Löfgren, Linda Morrow, Joanna Parkinson, Tina Rydén-Bergsten, Elaine Watkins, Maria Sörhede Winzell. PLoS ONE 13(12):e02208998. 

An oral antisense oligonucleotide for PCSK9 inhibition.

Peter Gennemark, Katrin Walter, Niclas Clemmensen, Dinko Rekić, Catarina A.M. Nilsson, Jane Knöchel, Mikko Hölttä, Linda Wernevik, Birgitta Rosengren, Dorota Kakol-Palm, Yanfeng Wang, Rosie Z. Yu, Richard S. Geary, Stan J. Riney, Brett P. Monia, Rikard Isaksson, Rasmus Jansson-Löfmark, Cristina S. J. Rocha,  Daniel Lindén, Eva Hurt-Camejo, Rosanne Crooke, Lloyd Tillman, Tina Rydén-Bergsten, Björn Carlsson, Ulf Andersson, Marie Elebring, Anna Tivesten and Nigel Davies. Science Translational Medicine  12 May 2021:Vol. 13, Issue 593, eabe9117.

A Case-Study of Model-Informed Drug Development of a Novel PCSK9 Anti Sense Oligonucleotide.

Part 1: First time in Man to Phase 2" by Jane Knöchel, Catarina Nilsson, Björn CL Carlsson, Linda Wernevik, Alexis Hofherr, Peter Gennemark, Rasmus Jansson-Löfmark, Rikard Isaksson, Tina Rydén-Bergsten, Bengt Hamren, and Dinko Rekic. Pharmacometrics Syst Pharmacol 2022 Dec;11(12):1569-1577

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.

Dinko Rekić, Ivan Azarov, Jane Knöchel, Victor Sokolov, Catarina Nilsson, Linda Wernevik, David Han, Tina Rydén-Bergsten, Ahmad Ebrahimi, Corina Dota, Björn Carlsson. Br J Clin Pharmacol. 2022;88:4839-4844. 

Veeva ID: Z4-60858
Date if preparation: February 2024